GLP-1 for Sleep Apnea: What They Cost

Updated April 20, 2026

In December 2024, Zepbound became the first and only medication approved by the FDA for obstructive sleep apnea (OSA) in adults with obesity. Mounjaro followed with its own sleep apnea indication in 2025. These two tirzepatide medications are currently the only GLP-1s FDA-approved for sleep apnea specifically — and that approval has a real impact on how much you'll pay.

This guide covers what they cost, why the sleep apnea indication can actually lower your price compared to a weight-loss-only prescription, and how to access them.

Why GLP-1s for Sleep Apnea?

Roughly 70% of adults with obstructive sleep apnea are also overweight or obese. Excess tissue around the upper airway narrows it during sleep, causing the breathing interruptions that define OSA. Weight loss reduces that tissue and reopens the airway. In Zepbound's Phase 3 trial, patients achieved clinically meaningful reductions in apnea-hypopnea index (AHI) events alongside weight loss.

The FDA approval is specifically for adults with obesity AND moderate-to-severe OSA — not for OSA alone in patients at normal weight.

Zepbound for Sleep Apnea

Zepbound (tirzepatide) is FDA-approved for both chronic weight management and obstructive sleep apnea. Same drug, same dosing, just a broader label.

• TrumpRx self-pay: $299/month flat, all doses
• LillyDirect: $299 (2.5mg starter), $399 (5mg), $449 (7.5mg+)
• Savings card (commercial insurance, covered plan): $25/month
• Savings card (not covered): Up to $650 off per fill
• Patient assistance via Lilly Cares: Free if income-qualified

Mounjaro for Sleep Apnea

Mounjaro (tirzepatide) received its sleep apnea indication in 2025. Pricing:

• TrumpRx self-pay: $350/month flat, all doses
• LillyDirect: No longer available
• Savings card (covered): $25/month
• Savings card (not covered): Up to $499 off per fill
• Patient assistance: Not available (Mounjaro is not on Lilly Cares)

Side-by-Side Comparison for Sleep Apnea

The Insurance Angle: Sleep Apnea Is a Better Indication Than Weight Loss Alone

Here's why your prescribed indication matters for cost:

• Zepbound for weight management alone: 30–40% commercial coverage rate. Insurance often rejects.
• Zepbound for obstructive sleep apnea: 40–50% commercial coverage rate. Higher approval odds.
• Zepbound for both: Same 40–50% coverage rate, same $25/mo savings card access when covered.

Translation: if you have both weight concerns and diagnosed sleep apnea, ask your prescriber to include the sleep apnea diagnosis on the prescription. It meaningfully improves your chances of insurance approval. Both conditions can be documented simultaneously and it's clinically appropriate.

What You'll Need to Qualify

For insurance approval with the sleep apnea indication, most plans require:

• Confirmed OSA diagnosis via overnight sleep study (polysomnogram) or validated home sleep test
• Apnea-hypopnea index (AHI) ≥ 5 events/hour (moderate or severe preferred; mild may still qualify)
• BMI ≥ 30, or ≥ 27 with comorbidity, matching the FDA label
• Prior CPAP trial documented in most cases (either tolerated and continued, or not tolerated)

GLP-1s are not replacements for CPAP for most patients — most clinical guidelines still recommend CPAP as first-line. But Zepbound and Mounjaro are approved as adjunctive or alternative therapy for qualifying patients.

Medicare Coverage for Sleep Apnea Indication

Medicare Part D coverage of tirzepatide for sleep apnea varies by plan and is still in flux. Many plans list Mounjaro as covered for Type 2 diabetes and have added sleep apnea coverage as the indication expanded. Zepbound coverage specifically for sleep apnea is less predictable. Check your plan's formulary directly.

The Medicare GLP-1 Bridge (launching July 2026) covers Zepbound at $50/month for weight management. Sleep apnea as a separate indication may provide additional coverage pathways through Part D formularies.

Medicaid Coverage for Sleep Apnea

State Medicaid coverage of Mounjaro and Zepbound for sleep apnea varies. Some states cover the sleep apnea indication more generously than weight loss alone because OSA is considered a medical condition rather than a lifestyle-related one. Check your state's specific policy or call Medicaid member services.

If You Can't Get Insurance Coverage

Self-pay fallback: Zepbound at $299/month on TrumpRx is cheaper than Mounjaro at $350/month. Both work equivalently for sleep apnea (same molecule). If your doctor is flexible on brand, Zepbound saves $51/month.

Bottom Line

• Both Zepbound and Mounjaro are FDA-approved for obstructive sleep apnea.
• Zepbound is cheaper self-pay ($299 vs $350).
• Insurance coverage rates for sleep apnea indication (40–50%) beat weight-loss-alone (30–40%).
• If you have both weight and OSA concerns, include OSA in your prescription to maximize coverage odds.
• Zepbound has a patient assistance program (Lilly Cares); Mounjaro doesn't.